The simultaneous $500M ATM and $500M buyback authorization creates a complex signal — management sees stock as undervalued (buyback) but wants capital flexibility (ATM). Monitor actual ATM usage vs. buyback execution in coming quarters; heavy ATM usage would signal capital needs despite strong cash position. The Q1 revenue beat and pipeline catalysts (three NDAs in 2026) provide fundamental support, but the ATM overhang may cap near-term upside. Watch for insider selling patterns and any accelerated ATM draws.
Price Chart
Executive Summary
BridgeBio Pharma filed an automatic shelf registration (S-3ASR) to register an unlimited amount of securities, including a $500 million at-the-market (ATM) common stock offering via Goldman Sachs and Leerink Partners. The filing comes one day after reporting strong Q1 2026 results with $194.5M in total revenue, $180.6M in U.S. Attruby net product revenue, and $940.2M in cash, alongside a newly authorized $500M share repurchase program. The ATM offering provides capital flexibility but creates potential dilution of up to ~3.8% of shares outstanding at current prices.
Key Facts
- S-3ASR filed May 7, 2026 registering unlimited securities, with a $500M ATM common stock offering via Goldman Sachs and Leerink Partners
- Q1 2026 total revenues of $194.5M, including $180.6M U.S. Attruby net product revenue, $9.5M royalty revenue, and $4.4M license/services revenue
- Cash, cash equivalents, and marketable securities of $940.2M as of March 31, 2026
- Board authorized a $500M share repurchase program concurrently with the ATM offering
- 195,707,702 shares outstanding as of March 31, 2026; up to 7,343,222 shares could be sold at $68.09/share to raise full $500M (3.8% dilution)
- Sales agents receive up to 3.0% commission on gross proceeds from ATM sales
- Proceeds intended for general corporate purposes including R&D, commercialization, working capital, debt repayment, and potential acquisitions
- Three late-stage pipeline candidates (BBP-418, encaleret, infigratinib) with NDAs submitted or planned for 2026
Financial Impact
Up to $500M in potential equity issuance at-the-market, representing ~3.8% dilution at current price; partially offset by $500M buyback authorization creating potential net neutral capital return
Risk Factors
- ATM sales could pressure stock price through continuous selling into the market
- Dilution of up to 3.8% if full $500M is drawn at current prices
- Buyback may not offset dilution if ATM is used aggressively
- Biotech sector volatility and regulatory risks for pipeline candidates
- Convertible debt overhang (~37.8M shares reserved for conversion across four note series)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001140361-26-019654 |
| Document: ny20072667x1_ex4-4.htm | 0001140361-26-019654 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access